3 February 2016 - From 1 March 2016, the effect of the decision is that:

• There will be a reduction in expenditure for budesonide with eformoterol inhalers (Symbicort Turbuhaler and Vannair); and
• The funding restrictions for budesonide with eformoterol in Section B and Part II of Section H of the Pharmaceutical Schedule will be removed

For more details, go to: http://www.pharmac.govt.nz/news/notification-2016-02-03-budesonide-eformoterol/